Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;16(1):998-1002.
doi: 10.3892/ol.2018.8709. Epub 2018 May 16.

Analysis of miR-148b expression differences in stage-I and II parosteal osteosarcoma

Wenjun Lin  1 , Lu Wang  1 , Shengwu Yang  1 , Xin Chen  1 , Xiongbai Zhu  1 , Piji Chen  2
Affiliations

Analysis of miR-148b expression differences in stage-I and II parosteal osteosarcoma

Wenjun Lin et al. Oncol Lett. 2018 Jul.

Abstract

Expression of human serum albumin-micro RNA miR-148b in patients with stage-I and II parosteal osteosarcoma and its effect on prognosis were investigated. A total of 47 cases of fresh tissues of stage-I and II parosteal osteosarcoma and the corresponding para-carcinoma normal bone tissues resected by operation were collected; the expression of miR-148b in parosteal osteosarcoma tissues and normal bone tissues was detected, and the correlations of miR-148b expression in parosteal osteosarcoma tissues with clinicopathological parameters and prognosis were analyzed. The expression level of miR-148b in parosteal osteosarcoma tissues was significantly lower than that in para-carcinoma normal tissues (P<0.05). It was found that the low expression of miR-148b was correlated with the lung metastasis (P<0.05). Moreover, Kaplan-Meier survival curve analysis showed that the overall survival rate of patients in the low-expression miR-148b group was lower than that in the high-expression group (P<0.05). Multivariate Cox regression analysis revealed that the miR-148b level (P=0.003) was an independent prognostic factor affecting the prognosis. The results of this study showed that the expression of miR-148b in stage-I and II parosteal osteosarcoma tissues declines, which is related to the poor clinical prognosis of parosteal osteosarcoma.

Keywords: 5-year survival rate; RT-qPCR; miR-148b; parosteal osteosarcoma; prognosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Expression of miRNA-148b in parosteal osteosarcoma tissues and para-carcinoma normal tissues; compared with that in para-carcinoma normal tissues, the expression of miRNA-148b in parosteal osteosarcoma tissues is significantly lower (*P<0.05).
Figure 2.
Figure 2.
Kaplan-Meier survival curves of high- and low-expression miRNA-148b groups; the survival rate in the high-expression group is significantly higher than that in the low-expression group (P<0.05).
See this image and copyright information in PMC

References

    1. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–3035. doi: 10.1200/JCO.2014.59.4895. - DOI - PMC - PubMed
    1. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–532. doi: 10.1016/j.ctrv.2013.11.006. - DOI - PubMed
    1. Azizi M, Teimoori-Toolabi L, Arzanani MK, Azadmanesh K, Fard-Esfahani P, Zeinali S. MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther. 2014;15:419–427. doi: 10.4161/cbt.27630. - DOI - PMC - PubMed
    1. Zhang JG, Shi Y, Hong DF, Song M, Huang D, Wang CY, Zhao G. MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway. Sci Rep. 2015;5:8087. doi: 10.1038/srep08087. - DOI - PMC - PubMed
    1. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 2012;56:1371–1383. doi: 10.1016/j.jhep.2011.11.026. - DOI - PubMed